EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study

Irene Dogliotti iD, Veronica Peri, Michele Clerico, Francesco Vassallo, Davide Musto, Silvio Mercadante, Simone Ragaini, Barbara Botto, Mario Levis, Mattia Novo, Marco Ghislieri, Luca Molinaro und 9 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.7448 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Irene Dogliotti und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, University Hospital A.O.U. "Città della Salute e della Scienza", Turin, Italy. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Rituximab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Relapse and refractory (R/R) rates after first‐line R‐CHOP in diffuse large B cell lymphomas (DLBCL) are ~40% and ~15% respectively.

Aims

We conducted a retrospective real‐world analysis aimed at evaluating clinical outcomes of R/R DLBCL patients. Material and Methods Overall, 403 consecutive DLBCL patients treated in two large hematological centers in Torino, Italy were reviewed.

Results

At a median follow up of 50 months, 5‐year overall survival from diagnosis (OS‐1) was 66.5%, and 2‐year progression free survival (PFS‐1) was 68%. 134 (34.4%) patients relapsed ( n = 46, 11.8%) or were refractory ( n = 88, 22.6%) to R‐CHOP. Most employed salvage treatments included platinum salt‐based regimens in 38/134 (28.4%), lenalidomide in 14 (10.4%). Median OS and PFS after disease relapse or progression (OS‐2 and PFS‐2) were 6.7 and 5.1 months respectively. No significant difference in overall response rate, OS‐2 or PFS‐2 in patients treated with platinum‐based regimens versus other regimens was observed. By multivariate analysis, age between 60 and 80 years, germinal center B cell type cell of origin and extranodal involvement of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseRituximabAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultAged, 80 and overNeoplasm Recurrence, LocalTreatment OutcomeDrug Resistance, NeoplasmYoung AdultPrednisoneSalvage TherapyItalyCyclophosphamideVincristineProgression-Free SurvivalDoxorubicin

Stichwörter der Autor:innen

chemotherapydiffuse large B cell lymphomareal worldrefractory diseaserelapserituximabtransplantation

Substanzen

RituximabPrednisoneR-CHOP protocolCyclophosphamideVincristineDoxorubicin

Autor:innen und Institutionen

  • Division of Hematology, University Hospital A.O.U. "Città della Salute e della Scienza", Turin, Italy.
  • Division of Hematology U, Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy.
  • Division of Hematology, Ospedale Santa Croce e Carle, Cuneo, Italy.
  • Division of Hematology, AOU "Città della Salute e della Scienza di Torino", Turin, Italy.
  • Division of Radiotherapy, Department of Oncology., University Hospital A.O.U. "Città della Salute e della Scienza", Turin, Italy.
  • Department of Electronics and Telecommunications, Politecnico di Torino, Turin, Italy.

ORCID-Profile: Irene Dogliotti, Benedetto Bruno, Federica Cavallo

Zitieren

APA

Dogliotti, I., Peri, V., Clerico, M., Vassallo, F., Musto, D., Mercadante, S., Ragaini, S., Botto, B., Levis, M., Novo, M., Ghislieri, M., Molinaro, L., Mortara, U., Consoli, C., Lonardo, A., Bondielli, G., Ferrero, S., Freilone, R., Ricardi, U., …, & Cavallo, F. (2024). Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study. Cancer Medicine. https://doi.org/10.1002/cam4.7448

Vancouver

Dogliotti I, Peri V, Clerico M, Vassallo F, Musto D, Mercadante S, et al. Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study. Cancer Medicine. 2024. doi:10.1002/cam4.7448

BibTeX
@article{Dogliotti2024,
  author = {Dogliotti, Irene and Peri, Veronica and Clerico, Michele and Vassallo, Francesco and Musto, Davide and Mercadante, Silvio and Ragaini, Simone and Botto, Barbara and Levis, Mario and Novo, Mattia and Ghislieri, Marco and Molinaro, Luca and Mortara, Umberto and Consoli, Chiara and Lonardo, Alessio and Bondielli, Giulia and Ferrero, Simone and Freilone, Roberto and Ricardi, Umberto and Bruno, Benedetto and Cavallo, Federica},
  title = {Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7448}
}
Kostenlos starten →